<DOC>
	<DOCNO>NCT00992706</DOCNO>
	<brief_summary>RATIONALE : F511 cream may prevent reduce palmar-plantar erythrodysesthesia woman receive doxorubicin hydrochloride liposome metastatic breast cancer . PURPOSE : This randomized phase III trial study F511 cream see well work compare placebo cream prevent palmar-plantar erythrodysesthesia patient receive doxorubicin hydrochloride liposome metastatic breast cancer .</brief_summary>
	<brief_title>F511 Cream Preventing Palmar-Plantar Erythrodysesthesia Patients Receiving Doxorubicin Hydrochloride Liposome Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate effect F511 cream occurrence palmar-plantar erythrodysesthesia ( PPE ) patient metastatic breast cancer treat pegylated liposomal doxorubicin hydrochloride . OUTLINE : This multicenter study . Patients receive pegylated liposomal doxorubicin hydrochloride accord local practice 1 , 2 , 4 week course schedule least 10 mg/m^2 per week allow . Patients apply F511 cream one side , hand foot correspond placebo side hand foot daily ( morning ) first week first pegylated liposomal doxorubicin hydrochloride treatment , daily , three time per week thereafter . Treatment continue throughout chemotherapy administration absence palmar-plantar erythrodysesthesia ( PPE ) ≥ grade 2 After completion study therapy , patient follow 30 day . Patients PPE ≥ grade 2 follow PPE resolve ≤ grade 1 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic breast cancer No cutaneous metastasis hand foot Pegylated liposomal doxorubicin hydrochloride monotherapy indicate accord local investigator Planned dose least 10 mg/m^2 per week No sign palmarplantar erythrodysesthesia ( PPE ) study entry PATIENT CHARACTERISTICS : WHO performance status 02 Able apply topical medication ( cream ) provide another person apply cream Not pregnant breastfeed Fertile patient must use effective contraception trial participation 1 month completion Negative pregnancy test Compliant geographically proximal order allow proper evaluation followup No dermatologic condition ( e.g. , psoriasis ) , opinion physician , may affect hand foot may complicate evaluation study treatment No known allergy hypersensitivity F511 cream PRIOR CONCURRENT THERAPY : See Disease Characteristics More 30 day since prior concurrent treatment experimental drug anticancer therapy More 30 day since prior concurrent treatment another clinical trial No concurrent local use ointment cream hand foot Excipial Repair®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>palmar-plantar erythrodysesthesia</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>